关键词: 心血管?肾脏?代谢综合征, 临床实践指南, 多学科协作

Abstract:  To address the substantial public health challenge posed by cardiovascular⁃kidney⁃metabolic (CKM) syndrome, the American Heart Association (AHA), American College of Cardiology (ACC), American Diabetes Association (ADA), The Obesity Society (TOS) and American Society of Nephrology (ASN) jointly released the first clinical practice guideline on CKM syndrome in 2026. The guideline recommends applying the 0-4 stage classification system, introduces the PREVENT equation for the precise quantification of cardiovascular risk, and establishes the core role of renin⁃angiotensin system inhibitors (RASi), sodium⁃glucose cotransporter⁃2 inhibitors (SGLT2i), glucagon⁃like peptide⁃1 receptor agonists (GLP⁃1RA), and finerenone. Notably, it incorporates the assessment of social determinants of health into routine management for the first time and advocates a multidisciplinary collaboration model centered on CKM coordinators, serving as a critical practical guide for the prevention, detection, evaluation, and management of CKM syndrome. While the guideline provides a framework for the management of CKM patients across diagnostic paradigms, risk stratification tools, intervention strategies, and health care system design, its application in China requires careful adaptation to account for population⁃specific differences between Chinese and Western cohorts.